cancer immunotherapy

Frazier to stay on as Merck CEO, as company axes retirement policy

https://pharmaphorum.com/news/frazier-to-stay-on-as-merck-ceo-as-company-axes-retirement-policy/

Latest lung cancer data could open new avenue for Roche’s Tecentriq

https://pharmaphorum.com/news/latest-lung-cancer-data-could-open-new-avenue-for-roches-tecentriq/

Communication problems holding back new cancer treatments

https://pharmaphorum.com/oncology/communication-problems-holding-back-new-cancer-treatments/

Affimed and Roche ink $5bn plus cancer immunotherapy deal

https://pharmaphorum.com/news/affimed-and-roche-ink-5bn-plus-cancer-immunotherapy-deal/

AbbVie takes option on Argenx’s cancer immunotherapy

https://pharmaphorum.com/news/abbvie-takes-option-on-argenxs-cancer-immunotherapy/

Oncolytics: the dawn of a new era in cancer treatment

https://pharmaphorum.com/views-analysis-oncology/oncolytics-new-era-cancer-treatment/

Immuno-Oncology Summit

https://pharmaphorum.com/events/immuno-oncology-summit/

Novel cancer immunotherapy research lands Innovate UK funding

https://pharmaphorum.com/news/novel-cancer-immunotherapy-research-lands-innovate-uk-funding/

BI strikes billion-dollar cancer immunotherapy deal with OSE

https://pharmaphorum.com/news/bi-strikes-billion-dollar-checkpoint-deal/

1 2 3 4 5 >»

Close in 10 seconds

Pharmaphorum.com

Search